WO2001076555A3 - Lipid-based drug delivery systems for topical application - Google Patents

Lipid-based drug delivery systems for topical application Download PDF

Info

Publication number
WO2001076555A3
WO2001076555A3 PCT/DK2001/000267 DK0100267W WO0176555A3 WO 2001076555 A3 WO2001076555 A3 WO 2001076555A3 DK 0100267 W DK0100267 W DK 0100267W WO 0176555 A3 WO0176555 A3 WO 0176555A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
drug delivery
delivery systems
topical application
based drug
Prior art date
Application number
PCT/DK2001/000267
Other languages
French (fr)
Other versions
WO2001076555A2 (en
Inventor
Kent Joergensen
Jesper Davidsen
Charlotte Vermehren
Sven Froekjaer
Ole G Mouritsen
Original Assignee
Liplasome Pharma As
Kent Joergensen
Jesper Davidsen
Charlotte Vermehren
Sven Froekjaer
Ole G Mouritsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma As, Kent Joergensen, Jesper Davidsen, Charlotte Vermehren, Sven Froekjaer, Ole G Mouritsen filed Critical Liplasome Pharma As
Priority to DE60126072T priority Critical patent/DE60126072T2/en
Priority to AU2001248301A priority patent/AU2001248301A1/en
Priority to JP2001574073A priority patent/JP2003530338A/en
Priority to EP01921261A priority patent/EP1272160B1/en
Priority to DK01921261T priority patent/DK1272160T3/en
Publication of WO2001076555A2 publication Critical patent/WO2001076555A2/en
Publication of WO2001076555A3 publication Critical patent/WO2001076555A3/en
Priority to CY20071100522T priority patent/CY1106462T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to lipid-based pharmaceutical or cosmetic compositions for use in the treatment, prevention or alleviation of diseases or conditions in skin or mucous membranes of mammals that are associated with or resulting from increased levels of extracellular phospholipase A2 (PLA2) activity in the tissue.
PCT/DK2001/000267 2000-04-12 2001-04-11 Lipid-based drug delivery systems for topical application WO2001076555A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60126072T DE60126072T2 (en) 2000-04-12 2001-04-11 LIPID-BASED DRUG DISPENSING SYSTEMS FOR TOPICAL APPLICATION
AU2001248301A AU2001248301A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
JP2001574073A JP2003530338A (en) 2000-04-12 2001-04-11 Lipid-based drug delivery system containing phospholipase A2 degradable lipid derivative for topical application to the skin
EP01921261A EP1272160B1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems for topical application
DK01921261T DK1272160T3 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery system for topical application
CY20071100522T CY1106462T1 (en) 2000-04-12 2007-04-16 LIPID BASED DRUG RELEASE SYSTEMS FOR TOPICAL APPLICATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200000616 2000-04-12
DKPA200000616 2000-04-12

Publications (2)

Publication Number Publication Date
WO2001076555A2 WO2001076555A2 (en) 2001-10-18
WO2001076555A3 true WO2001076555A3 (en) 2002-03-14

Family

ID=8159422

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/DK2001/000267 WO2001076555A2 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems for topical application
PCT/DK2001/000269 WO2001076644A2 (en) 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents
PCT/DK2001/000268 WO2001076556A2 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems against parasitic infections

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/DK2001/000269 WO2001076644A2 (en) 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents
PCT/DK2001/000268 WO2001076556A2 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems against parasitic infections

Country Status (11)

Country Link
US (4) US20030170297A1 (en)
EP (3) EP1272161B1 (en)
JP (3) JP2003530339A (en)
AT (2) ATE382333T1 (en)
AU (3) AU2001248301A1 (en)
CY (2) CY1105792T1 (en)
DE (3) DE60132184T2 (en)
DK (3) DK1272225T3 (en)
ES (3) ES2295149T3 (en)
PT (3) PT1272161E (en)
WO (3) WO2001076555A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
EP1391207A1 (en) * 2001-04-24 2004-02-25 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
US20050266066A1 (en) * 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
WO2005077963A1 (en) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais Saccharide and itol derivatives having an o-alkyl group or an o-alkyl group and an o-n butanyl group, uses as medicines in tumoral or benign proliferative pathologies
US20080113014A1 (en) * 2004-01-28 2008-05-15 Ltt Bio-Pharma Co., Ltd. Method for Screening for Compounds Safe for Gastric Mucosa
DE102004010387A1 (en) * 2004-03-03 2005-09-22 Siemens Ag Contrast agent for X-ray computed tomography
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
CN101325944B (en) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 Compositions for nasal delivery
EP1981488A1 (en) * 2005-12-23 2008-10-22 Jado Technologies GmbH Means and methods for the treatment and prevention of allergic diseases
JP2011026294A (en) * 2009-06-26 2011-02-10 Canon Inc Compound
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
US20120232034A1 (en) 2009-08-21 2012-09-13 Henk-Andre Kroon Vesicular formulations
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2013131164A1 (en) * 2012-03-09 2013-09-12 Universidade Federal De Minas Gerais - Ufmg Pharmaceutical composition containing conventional liposomes and prolonged-circulation liposomes for the treatment of visceral leishmaniasis
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
US20140079773A1 (en) * 2012-09-18 2014-03-20 Comfort Care For Animals Llc Encapsulating liposomes
ES2879383T3 (en) 2015-06-30 2021-11-22 Sequessome Tech Holdings Limited Mixed formulas
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638639A1 (en) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition and method for the production of oligolamellar liposomes for the purpose of application in cosmetology and topical dermatology
EP0475160A1 (en) * 1990-08-24 1992-03-18 Gregor Prof. Dr. Cevc Preparation for drug application in minute droplet form
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714865B2 (en) * 1986-10-28 1995-02-22 武田薬品工業株式会社 Liposome preparation and method for producing the same
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
JPH0370491A (en) 1989-08-04 1991-03-26 Toshiba Corp Motor controller
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4408011C1 (en) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Liposomes for tumour therapy
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638639A1 (en) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition and method for the production of oligolamellar liposomes for the purpose of application in cosmetology and topical dermatology
EP0475160A1 (en) * 1990-08-24 1992-03-18 Gregor Prof. Dr. Cevc Preparation for drug application in minute droplet form
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates

Also Published As

Publication number Publication date
CY1105792T1 (en) 2011-02-02
US20030170297A1 (en) 2003-09-11
US20070134153A1 (en) 2007-06-14
WO2001076556A2 (en) 2001-10-18
PT1272160E (en) 2007-04-30
WO2001076644A2 (en) 2001-10-18
DE60122304T2 (en) 2007-08-09
JP2003530338A (en) 2003-10-14
ES2280355T3 (en) 2007-09-16
AU2001248301A1 (en) 2001-10-23
ATE336267T1 (en) 2006-09-15
DK1272225T3 (en) 2006-12-27
EP1272160A2 (en) 2003-01-08
US20030162748A1 (en) 2003-08-28
ATE382333T1 (en) 2008-01-15
US7166297B2 (en) 2007-01-23
DE60126072D1 (en) 2007-03-08
EP1272225B1 (en) 2006-08-16
PT1272161E (en) 2008-02-08
DE60132184D1 (en) 2008-02-14
WO2001076555A2 (en) 2001-10-18
EP1272160B1 (en) 2007-01-17
US7368254B2 (en) 2008-05-06
EP1272225A2 (en) 2003-01-08
DE60126072T2 (en) 2007-11-08
JP2003530339A (en) 2003-10-14
AU2001248303A1 (en) 2001-10-23
EP1272161B1 (en) 2008-01-02
JP2003530362A (en) 2003-10-14
PT1272225E (en) 2007-01-31
DK1272160T3 (en) 2007-05-21
DE60132184T2 (en) 2009-01-15
EP1272161A2 (en) 2003-01-08
WO2001076556A3 (en) 2002-07-11
DK1272161T3 (en) 2008-05-19
AU2001248302A1 (en) 2001-10-23
ES2295149T3 (en) 2008-04-16
CY1106462T1 (en) 2012-01-25
ES2270991T3 (en) 2007-04-16
US20030175205A1 (en) 2003-09-18
WO2001076644A3 (en) 2002-03-14
DE60122304D1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2001076555A3 (en) Lipid-based drug delivery systems for topical application
EP1299374A4 (en) Novel non-psychotropic cannabinoids
BR9911071A (en) Preparations for the application of anti-inflammatory agents, especially antiseptics and / or agents that promote healing of wounds in the upper respiratory tract and / or the ear
MXPA05011208A (en) Topical formulation of ivermectin for the treatment of dermatological conditions.
BRPI0918868B8 (en) nmda receptor modulating compounds and compositions comprising the same
WO2002069963A3 (en) Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
ATE429922T1 (en) TOPICAL GEL DELIVERY SYSTEMS FOR THE TREATMENT OF SKIN DISEASES
NO20073615L (en) 3, 5-disubstituted and 3,5, 7-trisubstituted-3H-oxazolo and 3H-thiazolo [4,5-d] pyrimidin-2-one compounds and prodrugs thereof
BRPI0410721A (en) foamable pharmaceutical compositions and methods for treating a disorder
TW200801031A (en) Steroid nitrooxyderivatives
WO2007046097A3 (en) Topical compositions for the treatment of depilation-induced skin irritation or prevention thereof
IL174525A0 (en) Medicamentously targeted local lipolysis
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
HUP0400548A2 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
WO2008148573A3 (en) Medicament comprising an active substance combination containing pantothenic acid or the derivatives thereof for the treatment of allergy symptoms
TWI264312B (en) Highly flexible transdermal therapeutic system with nicotine as active ingredient
PT946157E (en) Topical use of KAPA-OPIOID AGONISTS FOR THE TREATMENT OF OCULAR PAIN
AU2003296692A1 (en) Lipidic protein-transfer systems and cosmetic/dermatological use thereof
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition
WO2000061231A3 (en) Medical use
WO2006086992A3 (en) Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
CY1109393T1 (en) THE USE OF ACHIEVEMENT FOR THE PREPARATION OF A MEDICINE THAT INDICATES VASCULATION
WO2008062110A3 (en) Cosmetic and/or pharmaceutical composition containing at least one peptide as the active ingredient and use of said peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001921261

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 574073

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001921261

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10239514

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2001921261

Country of ref document: EP